Association of MDR1 C1236T Polymorphisms and B Cell Non-Hodgkin Lymphoma

3Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Background: Multidrug resistance gene 1 (MDR-1) encodes for P-glycoprotein (P-gp) recognized for removing cytostatic drugs from tumor cells. MDR1 gene polymorphisms change function of P-gp. In this study, we are interested in investigating whether MDR1 C1236T single nucleotide polymorphisms (SNPs) affect the susceptibility and treatment-related toxicities in B-cell non-Hodgkin lymphoma (B-NHL) in the population of eastern China. Materials and methods: A group of 107 B-NHL patients and 150 healthy donors, unrelated ethnic Han Chinese and residents of eastern China, were included in this study. The MDR1 C1236T polymorphisms were determined using polymerase chain reaction-allele specific primers after extraction of genomic DNA. Analyses were performed using SPSS and Arlequin software. Results: MDR1 C1236T polymorphisms were not significantly related to the risk and treatment-related toxicities of B-NHL. A significant association between extranodal sites and C1236T allele was observed (C vs T: P=0.01). Conclusion: Our findings could expand our understanding of MDR1 in B-NHL and provide references for further research in multidrug resistance.

Cite

CITATION STYLE

APA

Zhang, W., Zhang, Q., Liang, H., Wang, S. L., Pan, J., Pan, S. Y., … Ni, Y. (2022). Association of MDR1 C1236T Polymorphisms and B Cell Non-Hodgkin Lymphoma. Journal of Cancer, 13(6), 1768–1772. https://doi.org/10.7150/jca.66312

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free